Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Citigroup Inc.

Citigroup Inc. raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 5.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 187,106 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,114 shares during the quarter. Citigroup Inc. owned 0.31% of Jazz Pharmaceuticals worth $24,661,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Tectonic Advisors LLC lifted its stake in Jazz Pharmaceuticals by 1.5% during the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock valued at $742,000 after purchasing an additional 82 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after acquiring an additional 90 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Jazz Pharmaceuticals by 3.5% during the 3rd quarter. Blue Trust Inc. now owns 3,261 shares of the specialty pharmaceutical company’s stock worth $430,000 after acquiring an additional 109 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in shares of Jazz Pharmaceuticals by 0.9% in the 3rd quarter. Arkadios Wealth Advisors now owns 13,948 shares of the specialty pharmaceutical company’s stock worth $1,838,000 after acquiring an additional 123 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its position in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — Jazz posted $6.64 EPS and $1.20B revenue, topping consensus and showing y/y revenue growth; investors view the print as confirmation of underlying demand. Earnings Call Summary
• Positive Sentiment: Company issued 2026 revenue guidance of $4.25B–$4.50B, in line with/near street expectations, reducing near‑term forecasting uncertainty and supporting the rally. Press Release
• Positive Sentiment: Strong product performance — Xywav ($1.7B, 12% y/y) and Epidiolex ($1.1B, 9% y/y) drove growth; Modeyso had a strong early launch ($37M in its first full quarter), supporting the top‑line beat. Product Sales Detail
• Positive Sentiment: Multiple analyst price‑target upgrades and bullish notes hit after the results (Bank of America to $275, Wells Fargo to $250, Morgan Stanley to $226, RBC to $195), amplifying buying interest from institutions and momentum traders. Analyst Upgrades
• Positive Sentiment: Pipeline progress: company expects to complete an sBLA submission for zanidatamab under RTOR in 1Q26 for HER2+ first‑line GEA — a successful filing/approval could materially expand oncology revenue over time. Pipeline & Guidance
• Neutral Sentiment: Management released the earnings slide deck and full call transcript — useful for digging into margin drivers, product cadence and assumptions behind 2026 guidance. Earnings Transcript
• Negative Sentiment: Profitability nuance: the company still showed a negative net margin in the quarter (impacted by non‑operating items and costs), so investors should watch whether earnings quality improves as 2026 progresses. Earnings Metrics
• Negative Sentiment: Valuation and risk: JAZZ trades at a relatively elevated P/E and carries leverage (debt/equity ~1.1); while analysts raised targets, some (RBC) show limited near‑term upside versus the current price — consider valuation vs. growth when sizing positions. Analyst Context

Jazz Pharmaceuticals Trading Up 13.2%

NASDAQ JAZZ opened at $196.83 on Thursday. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $197.47. The firm’s fifty day simple moving average is $168.72 and its 200-day simple moving average is $150.60. The company has a market capitalization of $11.96 billion, a PE ratio of -32.97, a price-to-earnings-growth ratio of 0.93 and a beta of 0.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 7.03% and a negative net margin of 8.35%.The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $6.51 earnings per share. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer owned 7,012 shares of the company’s stock, valued at $1,200,454.40. This represents a 39.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on JAZZ shares. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Wells Fargo & Company lifted their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday, January 12th. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $212.86.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.